Hepatitis
Steatosis impacts fibrosis progression in patients with mild hepatitis C
Published in Hepatitis Weekly, March 14th, 2005
"In patients with mild hepatitis C, the usefulness of antiviral therapy is subject of debate, as a low risk for progression of fibrosis is assumed. Several studies have shown that steatosis is a strong and independent predictor of the severity as well as the progression of fibrosis in chronic hepatitis C," scientists in France report.
"Therefore, this study assessed the impact of steatosis on the progression of fibrosis between paired liver biopsies in untreated patients with mild hepatitis on index biopsy," said L. Fartoux and colleagues, Public Assistance Hospital of Paris,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2005-03-14)
More Articles from Hepatitis Weekly
- Chronic Liver Disease
Protein profiles find cancer markers in patients with chronic liver disease - Diagnostics
Hepatitis B virus DNA remains stable in multiple freeze-thaw cycles - Diagnostics
Noninvasive elastography assesses hepatitis C-related fibrosis progression - Oncology
Gene sets identify hepatitis B virus-related liver cancer - Allergy and Immunology
Thymalfasin shows promise for treating viral hepatitis and cancer - Bipolar Disorder
Patient psychiatric evaluations are essential before liver transplantation - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
